Acute Ischemic Stroke Therapeutics Market Size 2024-2028

The acute ischemic stroke therapeutics market size is estimated to grow/decline by USD 1.74 billion at a CAGR of 6.1% between 2023 and 2028. The market is witnessing significant growth due to the rising prevalence of cardiovascular diseases, which is a leading cause of stroke. The integration of genomic and clinical data through translational bioinformatics in acute ischemic stroke management is another major trend driving market growth. This approach enables healthcare professionals to make informed decisions regarding patient treatment and improves patient outcomes. Additionally, there is an unmet need for anticoagulant reversal agents to effectively manage intracranial hemorrhage associated with thrombolytic therapy. These factors are expected to fuel market growth in the coming years.

What will be the Size of the Market During the Forecast Period?

To learn more about this report, Request Free Sample

Who are the Major  Market Players?                                     

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market 

Pfizer Inc- The company is engaged in the discovery, and development, manufacturing, marketing, sales, and distribution of biopharmaceutical products worldwide. The company's key offerings include acute ischemic stroke therapeutics such as Plavix.

We also have detailed analyses of the market's competitive landscape and offer information on 20 market companies, including :

• Athersys Inc.
• Bayer AG
• Biogen Inc.
• Boehringer Ingelheim International GmbH
• Medtronic Plc
• NoNO Inc.
• SanBio Co Ltd.
• Stryker Corp.
• Amgen Inc.
• AstraZeneca Plc
• Bristol Myers Squibb Co.
• Daiichi Sankyo Co. Ltd.
• F. Hoffmann La Roche Ltd.
• Johnson & Johnson
• Merck & Co. Inc.
• Sanofi SA
• Teva Pharmaceutical Industries Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak. 

Market Segmentation

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million " for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.

• Type Outlook
  • Thrombolytics
  • Anticoagulants
  • Antiplatelets
  • Antihypertensives
• Distribution Channel Outlook
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of World (ROW)
    • Argentina
    • Brazil
    • Chile

By Type Insights

The market share growth by the thrombolytics segment will be significant during the forecast period. Acute Ischemic Stroke (AIS) is a medical condition characterized by the sudden interruption of blood flow to the brain due to the formation of blood clots in the arteries supplying the brain. AIS is a leading cause of long-term disability and mortality, particularly among the aging population and those with comorbidities such as high blood pressure, diabetes, and obesity. The diagnosis of AIS involves a combination of medical history, physical examination, and neuroimaging techniques, including computed tomography (CT), Magnetic Resonance Imaging (MRI), carotid ultrasound, cerebral angiography, electrocardiography, and echocardiography. 

Get a glance at the market contribution of various segments Download PDF Sample

The thrombolytics segment showed a gradual increase in market share, from USD 2.61 billion in 2018. Several therapeutic approaches are available for the treatment of AIS, including Carotid Endarterectomy, Angioplasty, Endovascular Mechanical Thrombectomy, and the administration of thrombolytic agents. Thrombolytics are clot-dissolving drugs that are used to break down blood clots in the blood vessels. These agents include tissue plasminogen activator (tPA), alteplase, and tenecteplase, which belong to the drug class of thrombolytics. The process of breaking a blood clot is called thrombolysis. Neuroimaging technologies, such as CT scans and MRI scans, play a crucial role in the diagnosis and treatment of acute ischemic stroke (AIS). These techniques help to identify the location and extent of the blood clot, as well as any associated brain cell damage. The Defense Health Agency recommends the use of CT scans as the initial diagnostic tool for AIS due to their availability, speed, and ability to rule out other conditions that may mimic stroke symptoms. In conclusion, the treatment of AIS involves a combination of surgical and medical interventions, including thrombolytic agents, surgical procedures, and neuroimaging techniques. Thrombolytics, such as tPA, alteplase, and tenecteplase, are effective in breaking down blood clots and restoring blood flow to the brain. Surgical procedures, such as Carotid Endarterectomy and Angioplasty, are used to remove atherosclerosis plaques and improve blood flow. Neuroimaging technologies, such as CT scans and MRI scans, are essential for the diagnosis and monitoring of AIS.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample

North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The market encompasses a range of treatments aimed at mitigating the damaging effects of ischemic strokes. Key therapeutic classes include anticoagulants, statins, antihypertensives, and other drug classes

Furthermore,  anticoagulants, such as heparin and warfarin, prevent blood clots from forming and obstructing blood flow to the brain. Statins, used for managing cholesterol levels, have been linked to a reduced risk of ischemic stroke. Antihypertensives, which lower blood pressure, are essential in preventing and managing stroke risk. Other drug classes, like thrombolytics and antiplatelet agents, also play significant roles. The route of administration for these therapies includes both oral and parenteral forms. Distribution channels for these treatments span hospital pharmacies, retail pharmacies, and online pharmacies, ensuring accessibility to patients in various healthcare settings.

Buy Full Report Now

Market Dynamics and Customer Landscape

Acute Ischemic Stroke (AIS) is a medical condition characterized by sudden interruption of blood supply to the brain, leading to neurological deficits. Early intervention is crucial to minimize brain damage and improve patient outcomes. Imaging techniques such as computed tomography (CT), magnetic resonance imaging (MRI), carotid ultrasound, cerebral angiography, electrocardiography (ECG), and echocardiography aid in diagnosis. Treatment modalities include carotid endarterectomy, angioplasty, endovascular mechanical thrombectomy, and administration of thrombolytics like alteplase and tenecteplase. These drugs belong to thrombolytics, anticoagulants, and antiplatelet classes. Other drug classes used in AIS treatment include antihypertensives, statins, and antiplatelets. The route of administration varies, with some drugs given orally and others parenterally. The distribution channel for AIS therapeutics includes hospital pharmacies and retail pharmacies. Atherosclerosis plaques in blood vessels are the primary cause of AIS, making research and development of new treatments a priority. Our researchers analyzed the market research and growth data with 2023  as the base year, along with the key market growth analysis, trends, and challenges. A holistic analysis of drivers, trends, and challenges will help companies refine their marketing strategies to gain a competitive advantage. 

Key Market Drivers

Rising prevalence of cardiovascular diseases is notably driving market growth. Acute Ischemic Stroke (AIS) is a debilitating condition caused by the interruption of blood flow to the brain due to the formation of blood clots or atherosclerosis plaques in the arteries. This condition, which accounts for approximately 87% of all strokes according to the Centers for Disease Control and Prevention (CDC), can lead to irreversible brain cell damage and disability if not treated promptly. Neuroimaging techniques such as Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Carotid Ultrasound, Cerebral Angiography, Electrocardiography (ECG), and Echocardiography play a crucial role in diagnosing AIS.

Furthermore, Surgical equipment like Carotid Endarterectomy and Angioplasty are employed for removing the plaques, while Thrombolytics such as alteplase and tenecteplase, Anticoagulants, Antiplatelets, and Antihypertensives are used to dissolve blood clots and restore blood flow. The aging population, high blood pressure, diabetes, and obesity are significant risk factors for AIS. Neuroimaging technologies continue to evolve, with CT scans and MRI scans being the most commonly used methods for diagnosing AIS. The Defense Health Agency recommends the administration of thrombolytics like alteplase and tenecteplas within three to four and a half hours of the onset of symptoms to minimize brain damage. Thus, such factors are driving the growth of the market during the forecast period.

Significant Market Trends

Integrating genomic and clinical data through translational bioinformatics in acute ischemic stroke management is the key trend in the market. Acute Ischemic Stroke (AIS) is a debilitating neurological condition caused by the obstruction of blood flow to the brain due to the formation of blood clots from atherosclerosis plaques in the arteries. Diagnosis of AIS involves a combination of medical history, physical examination, and neuroimaging techniques such as Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Carotid Ultrasound, Cerebral Angiography, Electrocardiography, and Echocardiography. Treatment modalities include Carotid Endarterectomy, Angioplasty, Endovascular Mechanical Thrombectomy, and administration of Clot dissolving drugs like Tissue Plasminogen Activator (alteplase, tenecteplase) and Anticoagulants, Antiplatelets, and Antihypertensives.

Furthermore, the aging population, high blood pressure, diabetes, and obesity are significant risk factors for AIS. Neuroimaging technologies are essential in the diagnosis and management of AIS, and the Defense Health Agency highligts the importance of these technologies in improving patient outcomes. Surgical equipment and interventional procedures like Mechanical thrombectomy are critical in restoring blood flow and minimizing brain cell damage. TBI, or Translational Bioinformatics, is a computational technology that integrates and analyzes data obtained from various sources, including bioinformatics, biostatistics, statistical genetics, and clinical informatics, to enhance clinical guidelines for treating and preventing AIS. It acts as a data-storage source, using tools such as Ontologies and Controlled vocabulary, to provide a standard way for data representation and acceptance by specific user communities, such as Gene Ontology and the Systematized Nomenclature of Medicine-Clinical Terms (SNOMED-CT). Thus, such trends will shape the growth of the market during the forecast period.

Major Market Challenges

Unmet needs for anticoagulant reversal agents is the major challenge that affects the growth of the market. Acute Ischemic Stroke (AIS) is a medical condition characterized by the sudden interruption of blood flow to the brain, often caused by the formation of blood clots due to atherosclerosis plaques in the arteries supplying the brain. Diagnosis of AIS involves a combination of medical history, physical examination, and neuroimaging techniques such as Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Carotid Ultrasound, Cerebral Angiography, Electrocardiography, and Echocardiography. Treatment options include Carotid Endarterectomy, Angioplasty, Endovascular Mechanical Thrombectomy, and administration of Clot dissolving drugs like Tissue Plasminogen Activator (tPA) and tenecteplase.

Furthermore, surgical equipment is also used to restore blood flow and prevent further brain cell damage. Risk factors for AIS include aging population, high blood pressure, diabetes, and obesity. Novel anticoagulants are being developed to improve treatment outcomes, but their adoption is limited due to the unavailability of antidotes for anticoagulants in the market. Antidotes such as vitamin K, protamine, and prothrombin complex concentrates are used to reverse the effects of anticoagulants like warfarin and heparin, but their availability is limited. This can lead to safety concerns and limit the uptake of novel anticoagulants in the market. Hence, the above factors will impede the growth of the market during the forecast period

Market Customer Landscape

The market forecast report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market forecasting and growth strategies.

 Customer Landscape

Market Analyst Overview

Acute Ischemic Stroke (AIS) is a medical condition characterized by sudden interruption of blood flow to parts of the brain, leading to brain cell damage. AIS is often caused by atherosclerosis plaques in the arteries that result in the formation of blood clots. Acute myocardial infarction (AMI) and acute massive pulmonary embolism (PE) are both life-threatening conditions that require immediate medical intervention to prevent severe complications or death. Neuroimaging techniques such as computed tomography (CT) scans and magnetic resonance imaging (MRI) scans play a crucial role in diagnosing AIS. Surgical equipment like cerebral angiography, carotid ultrasound, electrocardiography (ECG), echocardiography, carotid endarterectomy, and angioplasty are used for both diagnosis and treatment.

Furthermore, thrombolytic drugs like tissue plasminogen activator (tPA) and alteplase, and anticoagulants, antiplatelets, antihypertensives are commonly used for clot dissolving and preventing further clot formation. The aging population, high blood pressure, diabetes, and obesity are significant risk factors for AIS. Stroke therapeutics encompass a range of treatments and interventions designed to minimize brain damage and improve recovery outcomes for stroke patients. Neuroimaging technologies continue to evolve, with endovascular mechanical thrombectomy emerging as a promising treatment option.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Market  Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting of the market between 2024 and 2028
• Precise estimation of the size of the market size and its contribution to the parent market
• Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
• Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
• Thorough market growth analysis of the market's competitive landscape and detailed information about companies
• Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies